Imatinib Resistance (ABL Kinase) Gene Analysis - IRMA near me in New Delhi

Imatinib resistance (ABL kinase) gene analysis, also known as IRMA, is specifically designed to evaluate genetic alterations (mutations) associated with resistance to imatinib therapy in patients with certain types of cancer, particularly those with abnormalities in the ABL kinase gene. Imatinib is a highly effective drug widely used for the treatment of chronic myeloid leukemia (CML), in which patients have demonstrated extremely high survival rates on imatinib treatment. However, some patients may develop resistance to imatinib over time, leading to treatment failure. This test aims to identify genetic changes in the ABL kinase gene that are responsible for this resistance. It helps in determining the therapeutic strategy by adjusting the Imatinib dose, switching to other drugs like Dasatinib or Nilotinib, or alternate treatment approaches.

Note: Genetic counseling can be provided. If interested, please send the request to this email id: [email protected]